Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (30)

2024

  1. Targeting IL-11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension-associated lung fibrosis

    British Journal of Pharmacology, Vol. 181, Núm. 16, pp. 2991-3009

2023

  1. Molecular and Clinical Predictors of Quality of Life in Chronic Rhinosinusitis with Nasal Polyps

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  2. Targeting IL-11 system as a treatment of pulmonary arterial hypertension

    Pharmacological research, Vol. 197, pp. 106985

2022

  1. IL-11 system participates in pulmonary artery remodeling and hypertension in pulmonary fibrosis

    Respiratory Research, Vol. 23, Núm. 1

  2. Increased Expression of Galectin-3 in Skin Fibrosis: Evidence from In Vitro and In Vivo Studies

    International Journal of Molecular Sciences, Vol. 23, Núm. 23

  3. The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. High-speed video microscopy for primary ciliary dyskinesia diagnosis: A study of ciliary motility variations with time and temperature

    Diagnostics, Vol. 11, Núm. 7

  2. MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor β inducing fibrotic responses

    Mucosal Immunology, Vol. 14, Núm. 2, pp. 377-388

2019

  1. In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients

    PLoS ONE, Vol. 14, Núm. 1

  2. MUC1 intracellular bioactivation mediates lung fibrosis

    Thorax, Vol. 75, Núm. 2, pp. 132-142

  3. Mucin 1 deficiency mediates corticosteroid insensitivity in asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 1, pp. 111-121

2018

  1. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

    Thorax, Vol. 73, Núm. 6, pp. 519-529

  2. The JAK2 pathway is activated in idiopathic pulmonary fibrosis

    Respiratory Research, Vol. 19, Núm. 1

2016

  1. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

    Respiratory Research, Vol. 17, Núm. 1

  2. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: An ex vivo/in vitro study

    European Respiratory Journal, Vol. 47, Núm. 6, pp. 1737-1749

2013

  1. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis

    Respirology, Vol. 18, Núm. 7, pp. 1056-1062

  2. Phosphodiesterase-4 inhibition improves corticosteroid insensitivity in pulmonary endothelial cells under oxidative stress

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 68, Núm. 1, pp. 64-73

  3. Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis

    Thorax, Vol. 68, Núm. 10, pp. 938-948

  4. Study of USH1 Splicing Variants through Minigenes and Transcript Analysis from Nasal Epithelial Cells

    PLoS ONE, Vol. 8, Núm. 2

2011

  1. A study of the effect of proinflammatory cytokines on the epithelial cells of smokers, with or without COPD

    Archivos de Bronconeumologia, Vol. 47, Núm. 9, pp. 447-453